9 recruiting, 3 completed, 2 active not recruiting, 2 unknown. 10 Phase 1, 7 Phase 2, 3 Phase 3, 1 Early Phase 1.
Follow Krystal Biotech, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease KB111 - Hailey Hailey Disease, Skin Diseases | Early Phase 1 | Recruiting | Krystal Biotech, Inc. | 7 | 2026-05-06 | 2026-07-21 |
| A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis KB801, Placebo - Neurotrophic Keratitis | Phase 1 / Phase 2 | Recruiting | Krystal Biotech, Inc. | 60 | 2025-07-07 | 2026-02-27 |
| A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa KB803, Placebo - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Recruiting | Krystal Biotech, Inc. | 16 | 2025-06-20 | 2026-03-12 |
| A Study Assessing KB304 for the Treatment of Wrinkles in Women KB304, 0.9% Normal Saline (NS) - Wrinkles in Decolletage, Pigmentation | Phase 1 / Phase 2 | Active not recruiting | Krystal Biotech, Inc. | 19 | 2024-11-20 | 2025-05-13 |
| A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB) Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive | Recruiting | Krystal Biotech, Inc. | 40 | 2024-08-02 | 2025-07-02 | |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy - Lung Cancer, Non-small Cell, Lung Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Krystal Biotech, Inc. | 250 | 2024-04-17 | 2025-10-24 |
| A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency KB408 (Nebulization) - Alpha 1-Antitrypsin Deficiency | Phase 1 | Recruiting | Krystal Biotech, Inc. | 15 | 2024-02-15 | 2025-07-22 |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) - Cancer, Melanoma Stage III | Phase 1 / Phase 2 | Recruiting | Krystal Biotech, Inc. | 240 | 2023-10-31 | 2025-05-18 |
| A Study Assessing KB407 for the Treatment of Cystic Fibrosis KB407 (Nebulization) - Cystic Fibrosis | Phase 1 | Recruiting | Krystal Biotech, Inc. | 20 | 2023-06-30 | 2026-05-07 |
| Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) KB105, Placebo - Autosomal Recessive Ichthyosis | Phase 2 | Unknown | Krystal Biotech, Inc. | 15 | 2023-03-01 | 2023-02-23 |
| A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis KB407 (Nebulization) - Cystic Fibrosis | Phase 1 | Withdrawn | Krystal Biotech, Inc. | 2022-03-08 | 2023-08-14 | |
| A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa Open Label Topical Beremagene Geperpavec (B-VEC) - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Completed | Krystal Biotech, Inc. | 47 | 2021-05-25 | 2024-04-09 |
| Long-Term Follow-up Protocol Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Recruiting | Krystal Biotech, Inc. | 50 | 2021-05-25 | 2021-06-08 | |
| A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions KB301, Placebo - Skin Roughness, Wrinkle | Phase 1 | Active not recruiting | Krystal Biotech, Inc. | 85 | 2020-10-07 | 2025-05-13 |
| Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB Topical Beremagene Geperpavec, Placebo - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Completed | Krystal Biotech, Inc. | 31 | 2020-08-17 | 2023-02-17 |
| The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB) Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Withdrawn | Krystal Biotech, Inc. | 2020-01-01 | 2021-09-17 | ||
| Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) KB105 - TGM-1 Related Autosomal Recessive Congenital Ichthyosis | Phase 1 / Phase 2 | Unknown | Krystal Biotech, Inc. | 6 | 2019-08-27 | 2021-09-13 |
| A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients Topical beremagene geperpavec, Placebo gel - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Completed | Krystal Biotech, Inc. | 12 | 2018-05-06 | 2023-01-31 |
Epidermolysis Bullosa Dystrophica (7) · Corneal Injuries (2) · Cystic Fibrosis (2) · Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Melanoma (1) · Pemphigus, Benign Familial (1) · Skin Diseases (1) · alpha 1-Antitrypsin Deficiency (1)
Docetaxel (1) · Drug Therapy (1) · Opdualag (1) · Saline Solution (1) · pembrolizumab (1)
United States (17) · Australia (1)
David Chien, MD (3) · David Sweet, MD, PhD (1)